来源：市场资讯 （来源：弗若斯特沙利文） 2026年2月13日，普莱医药-B首次向港交所递交招股书，拟在香港主板上市，独家保荐人为中信。 公司是一家领先创新型抗菌肽（「AMP」）治疗药物公司，2024年收入0.05亿元，净亏损1.58亿元。 2025年前9月收入0.03亿元，净亏损1.01亿元。 公司是一家于2009年4月成立的领先创新型抗菌肽（「AMP」）治疗药物公司，秉持「以科技创新服务 人类健康」的理念。公司专注于四个核心治疗领域，即抗感染、代谢疾病、肿瘤及自身免疫疾病，致力 于透过公司的专有突破性技术及候选药物解决全球重大未被满足的健康需求。 截至最后实际可行日期，公司有九种候选药物，包括一种核心产品（即PL-5）及两种主要产品（即PL- 3301及PL-18）。 涵盖感染性疾病、代谢性疾病、肿瘤及自身免疫性疾病。该等候选药物的目标适应症包括继发性创面感 染、糖尿病足感染（「DFI」）、外阴阴道念珠菌病（「VVC」）、口咽念珠菌病（「OPC」）、肺部 感染、全身感染、肥胖症、代谢功能障碍相关脂肪性肝炎（「MASH」）、溃疡性结肠炎 （「UC」）、实体瘤、血液肿瘤，及其他自身免疫性疾病。 根据弗若斯特沙 ...

Market Overview - The Hang Seng Index slightly declined by 0.20% to 26,595.97 points, while the Hang Seng Tech Index fell by 0.25% and the Hang Seng China Enterprises Index decreased by 0.32%. The market's half-day trading volume was HKD 118.31 billion [2]. Company Performance - Xpeng Motors (XPEV) saw a significant increase of 15.11%, while Baidu (BIDU) rose by 3.34% and Kingdee International (0268.HK) increased by 1.61%. Conversely, Tencent Music (TME) dropped by 2.35%, Alibaba (BABA) fell by 2.33%, and JD.com (JD) decreased by 2.09%. Tsinghua Tongfang (Tengsheng Bo Pharmaceutical) rose by 1.65% after presenting breakthrough data at the 2025 AASLD conference [2]. Industry Insights - Guotai Junan Securities reported that the valuation of the Hong Kong internet sector has become highly attractive after a prolonged adjustment. The latest price-to-earnings (PE) ratio for the Hang Seng Internet Technology Index is 21.73, placing it at the 16.67% historical low over the past decade, indicating that the sector is undervalued [3]. - A fundamental shift in the core narrative of the Hong Kong internet sector is occurring, moving from a focus on user growth and business models to the new growth curve brought by "AI empowerment." Recent developments, such as Alibaba's establishment of a "Robotics and Embodied AI Group" and Tencent's mixed-image model achieving first place in global blind tests, demonstrate that AI is transitioning from concept to practical application, potentially reshaping the market value of internet giants [3]. - The Hang Seng Internet ETF (513330) supports T+0 trading and focuses on the platform economy, including major internet leaders like Alibaba, JD.com, Tencent, Meituan, Kuaishou, and Baidu. With a DeepSeek content ratio of 86%, it possesses dual attributes of "new consumption + new technology," making it a suitable tool for investors looking to allocate resources to AI applications and "AI + internet" core assets [3].

Core Viewpoint - Hong Kong's biopharmaceutical stocks experienced a significant afternoon rally, indicating positive market sentiment in the sector [1] Company Performance - Yongtai Bio-B surged over 12% [1] - Kexing Pharmaceutical-B increased nearly 10% [1] - Tiansheng Pharmaceutical-B rose over 5% [1] - WuXi AppTec-B and Weisheng Pharmaceutical-B both gained over 3% [1]

Core Viewpoint - Hong Kong's biopharmaceutical stocks experienced a significant afternoon rally, indicating positive market sentiment in the sector [2] Group 1: Stock Performance - Yongtai Bio-B surged over 12% [2] - Keji Pharmaceutical-B increased nearly 10% [2] - Tiansheng Pharmaceutical-B rose over 5% [2] - WuXi AppTec-B and Weisheng Pharmaceutical-B both gained over 3% [2]

Core Viewpoint - The recent surge in the Hong Kong innovative drug sector, particularly the rise of companies like Health元, indicates a potential value reassessment in the market, especially in the inhalation drug segment, which is gaining renewed attention due to major acquisitions like Merck's purchase of Verona Pharma [1][2]. Group 1: Market Trends - The Hong Kong innovative drug sector has seen a significant increase, with the Shanghai Innovative Drug Index rising over 50% since April, marking it as one of the strongest themes of the year [1]. - Health元's stock price has only increased by about 20%, suggesting a potential undervaluation compared to its peers [1]. Group 2: Company Strategy - Health元 has strategically focused on the inhalation drug market, developing a comprehensive respiratory portfolio that includes PDE4 inhalation agents targeting mild to moderate COPD patients [2]. - The company has established a leading position in the inhalation drug space, with a pipeline that includes PDE4 inhalation agents, oral PREP inhibitors, and next-generation ICS inhalers, providing a robust solution for COPD treatment [2]. Group 3: Partnerships and Innovations - Health元 has partnered with Tsinghua University to gain exclusive rights to BRII-693, a new drug targeting drug-resistant infections, addressing a significant clinical need in China [3]. - The company is also advancing in the monoclonal antibody space, with products targeting IL-17A and PD-1 entering late-stage clinical trials, focusing on autoimmune diseases and cancer treatment [3]. Group 4: Policy Environment - The innovative drug sector is benefiting from favorable policies, with the National Healthcare Security Administration excluding innovative drugs from the latest procurement, alleviating profit margin concerns [4]. - The introduction of a commercial insurance support system for high-value drugs not included in basic medical insurance is expected to enhance payment pathways for innovative drugs [4]. Group 5: Investment Perspective - The market is shifting its preference towards platform and integrated companies rather than single-product firms, as these companies can leverage their pipeline and operational synergies for sustained cash flow and growth [5]. - Health元's current stock price remains below the average increase of most innovative drug indices, indicating that the market may be underestimating its dual identity as a leader in inhalation and integration [5].

Group 1: Market Overview - The Hang Seng Index rose by 0.07%, gaining 17 points to close at 24,534 points, while the Hang Seng Tech Index increased by 0.29% [1] - The early trading volume in the Hong Kong stock market reached HKD 128.7 billion [1] Group 2: Innovative Drug Sector - The innovative drug sector is experiencing a resurgence, driven by favorable policies and expectations from BD, with institutions noting that the current valuations remain attractive [1] - The Hang Seng Biotechnology Index surged by 4.41% [1] Group 3: Notable Stock Performances - Lepu Biotech-B (02157) saw a significant increase of over 13% [1] - Kangfang Biotech (09926) rose by 10.16% [1] - Kangruoya-B (02162) increased by 12.4% [1] - Sangfor Biopharma (01530) gained 8.94% [1] - Fudan Zhangjiang (01349) surged by 23.9% due to progress in ADC platform development [2] - King’s Ray Biotech (01548) increased by over 6%, with CARVYKTI sales in Q2 growing approximately 136% year-on-year [3] - Ascentage Pharma-B (06855) rose by 4.87%, with recent fundraising exceeding HKD 1.49 billion and the approval of a new drug application [4] - Terns Pharmaceuticals-B (02137) increased by over 6% after granting exclusive rights for a new drug in Greater China [5] - BeiGene (06160) rose by 8.39% after the acceptance of a listing application for a dual-specificity antibody [6] - Damai Entertainment (01060) increased by 7.27%, becoming the official channel for Scottish Super League matches [7] - Bilibili-W (09626) rose by over 4%, with growth in gaming and advertising business leading to a target price upgrade by Bank of America [8] - Fenbi (02469) surged by over 14% following the release of its AI test preparation program, with expectations of improved profit margins due to increased penetration [9] - Smoore International (06969) fell by 1%, with expected net profit decline of up to 35% in the first half of the year due to rising expenses [10]

Group 1: Market Performance - Bilibili-W (09626) rose over 4% due to growth in gaming and advertising, with Bank of America raising the target price to HKD 211 [1] - Innovation drugs continue to attract funding, with companies like 3SBio (01530) up over 8%, CanSino Biologics (09926) up over 12%, and others reaching historical highs [1] - DaMai Entertainment (01060) increased over 5% as it became the official channel for Scottish Super League matches, indicating growth in sports ticketing [1] Group 2: Industry Developments - The National Healthcare Security Administration of China initiated the 11th batch of centralized drug procurement, focusing on mature "old drugs" and excluding innovative drugs from the procurement [1] - In the first half of this year, the total amount of License out for Chinese innovative drugs approached USD 66 billion, surpassing the total BD transaction amount for 2024, indicating sustained interest from multinational corporations [1] Group 3: Company-Specific News - Meitu (01357) rose over 5% due to significant progress in overseas lifestyle and productivity scene expansion, including a strategic partnership with Alibaba [2] - Tengsheng Bo Pharmaceutical-B (02137) increased over 7% after granting exclusive rights for a new drug in Greater China to Health元 Group [2] - Smoore International (06969) fell over 2% as it expects a profit decline of up to 35% in the first half of the year due to increased expenses [2] Group 4: Notable Stock Movements - Blueport Interactive (08267) surged over 40% after establishing the LK Crypto division to accelerate Web3 and RWA layout [2] - Gilead Sciences-B (01672) saw an early morning increase of over 11% as clinical research for ASC47 in treating obesity was completed [2] - MicroPort Medical (0853.HK) rose over 6% as it considers a non-binding proposal to restructure its CRM business [3]

Core Insights - The phenomenon of Labubu, a unique IP, has sparked significant interest in the cultural and creative industry, highlighting the potential for local IP development in Shenzhen [1][3] - The discussion around Labubu's success reveals critical insights into consumer behavior, particularly among the younger demographic, and the importance of emotional value in driving sales [3][8] Consumer Engagement and Market Dynamics - Labubu's search popularity on Douyin increased by 97 times in two months, with 89% of its audience aged 18 to 40, predominantly female [3] - The success factors for Labubu include targeting Gen Z's emotional consumption needs, strong social attributes, effective use of new media for marketing, and the collectible value of blind box models [3][4] - The blind box model has created a speculative investment aspect, with hidden variants commanding premiums of up to ten times their original price [3] Industry Challenges and Opportunities - The development of successful IPs like Labubu requires long-term investment and consistent exposure, often taking a decade or more [10][11] - The rapid imitation of successful products poses a significant risk to original creators, highlighting the need for stronger IP protection [10][11] - Shenzhen's cultural industry is characterized by strong manufacturing capabilities but lacks in brand development and high-value segments of the value chain [11] Future Directions and Strategic Recommendations - There is a consensus on the need for a more integrated approach to IP development, combining design, marketing, and consumer psychology [12][14] - The government is encouraged to support local IPs through policy frameworks, marketing initiatives, and regulatory oversight to foster a sustainable creative ecosystem [14][15] - The cultural industry must address the emotional needs of consumers, providing deeper engagement and connection through its offerings [15]

Summary of Key Points from the Conference Call Industry Overview - The潮玩 (trendy toy) market is benefiting from macroeconomic development, with China's per capita GDP surpassing $12,000, shifting consumer spending from necessities to discretionary items, providing growth momentum for the潮玩 industry [1][2] - The IP toy market in China is projected to reach approximately 57.8 billion RMB by 2025, with an annual growth rate of about 20%, indicating a robust trend in the consumer sector [2] Core Insights and Arguments - IP toys account for about half of the sales in the潮玩 market, with blind boxes being the main driving force [1][2] - The rise of潮玩 brands is largely attributed to consumer-driven marketing, aesthetic appeal, third-party certification (such as going public), and social media dissemination, which reduces marketing costs and fosters a vibrant secondary market [1][4] - The core competitiveness of潮玩 includes aesthetic PUA (Pick Up Artist), third-party certification, and self-promotion, allowing brands like泡泡玛特 (Pop Mart) to attract young consumers and enhance brand credibility through unique designs and social attributes [1][5] Consumer Behavior and Market Dynamics - The purchase behavior of潮玩 and new consumer products is characterized by randomness, such as the uncertainty of obtaining rare cards or hidden items in blind boxes, which stimulates dopamine release and increases pleasure [8][9] - Blind boxes dominate the潮玩 market, accounting for over half of the sales due to their more appealing presentation compared to directly displayed products [8] Competitive Landscape -潮玩 companies can be categorized into three types: channel-based (e.g.,名创优品), third-party IP-based (e.g.,布鲁可, 卡游), and self-owned IP companies (e.g.,泡泡玛特). Self-owned IP companies are considered to have the most long-term value due to their rarity and sustainability [3][11][15] - Successful潮玩 brands like泡泡玛特 have gained credibility through third-party certification, unlike unsuccessful brands like暴力熊 (Bearbrick) and蒙奇奇 (Monchhichi), which lacked such validation [6][7] Additional Insights - The core competitiveness of self-owned IP companies lies in their ability to sustain operations, which determines whether an IP can remain relevant and profitable over time [13] - Companies using third-party IP for product sales can achieve growth by enhancing their operational and channel capabilities, focusing on exclusive IP acquisition to avoid homogenization and ensure profitability [14]

Policy Developments - The Ministry of Finance announced measures regarding the procurement of medical devices imported from the EU, stating that for procurement budgets over 45 million yuan, EU companies (excluding EU-funded enterprises in China) must be excluded if import products are required [1] Drug and Device Approvals - Weikang Pharmaceutical's Anruini capsules have been submitted for market approval, targeting adult and adolescent patients with specific solid tumors carrying NTRK fusion genes [2] - AstraZeneca's Imfinzi (Durvalumab) has received EU approval for use in muscle-invasive bladder cancer (MIBC) as an adjuvant treatment following radical cystectomy [3] Capital Market Activities - Micot announced the completion of over 100 million yuan in Series D financing, led by Zhejiang Merchants Venture Capital, with funds aimed at core pipeline development and the establishment of a formulation industrialization base [4] - Opcon Vision plans to use 334 million yuan to acquire 75% of Shanyang Qicheng Hospital Management Co., with part of the funds redirected from a community eye care service project [5] Industry Developments - Tengsheng Bo Pharmaceutical has reached a BD licensing agreement with Health元 for BRII-693, with Health元 responsible for development and commercialization in Greater China [7][8] - Nengte Technology has adjusted the listing price for the sale of its subsidiary, Ankang Shenqian Mining Co., to 114 million yuan, a 15% decrease from the previous listing price [9] - Ever Union, a shareholder of Mindray Medical, plans to reduce its stake by up to 0.41% through various legal means [10]